Comparative Pharmacology
Head-to-head clinical analysis: CLOTIC versus ENSTILAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTIC versus ENSTILAR.
CLOTIC vs ENSTILAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole is an imidazole antifungal that inhibits ergosterol synthesis by inhibiting 14α-demethylase (CYP51), leading to disruption of fungal cell membrane integrity and increased permeability.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical: Apply a thin layer to affected areas 2-4 times daily. Duration limited to 2 weeks; maximum 50 g/week. Intralesional: 0.5-1 mL of 10 mg/mL solution injected into lesion weekly.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2.5-4.5 h) in adults with normal renal function; extends to 6-8 hours in mild-moderate renal impairment.
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as inactive conjugates.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid and Vitamin D Analog